PARP Inhibition for Gliomas (PI-4G or π4g)

NCT05297864 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

15

Enrollment

OTHER

Sponsor class

Stopped Funder terminated funding.

Conditions

Recurrent Glioblastoma
Recurrent Astrocytoma
Recurrent Oligodendroglioma
Recurrent Glioma

Interventions

DRUG: Niraparib

Sponsor

University of Oklahoma

Collaborators

[object Object]